Daniel Gage

Title: The Innovations of Daniel Gage

Introduction

Daniel Gage is a notable inventor based in Waltham, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of Factor VIII polypeptide formulations. With a total of 3 patents to his name, Gage's work has the potential to impact the treatment of hemophilia.

Latest Patents

One of Gage's latest patents focuses on Factor VIII polypeptide formulations. This invention provides a formulation of a Factor VIII polypeptide, such as FVIII-Fc, along with methods of using the same. The FVIII polypeptide can be a recombinant FVIII protein, a short-acting FVIII protein, or a long-acting FVIII protein. The pharmaceutical formulation comprising a FVIII polypeptide can be utilized for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia.

Career Highlights

Gage has established himself as a key figure in the biotechnology sector. His work at Bioverativ Therapeutics Inc. has allowed him to focus on innovative solutions for hemophilia treatment. His expertise in polypeptide formulations has garnered attention in the medical community.

Collaborations

Throughout his career, Gage has collaborated with talented individuals such as Kevin Maloney and Ahmad Abdul-Fattah. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Daniel Gage's contributions to biotechnology, particularly in the area of Factor VIII polypeptide formulations, highlight his innovative spirit and dedication to improving hemophilia treatment. His work continues to pave the way for advancements in medical therapies.